ClinicalTrials.gg
CompletedNCT00463866Updated Mar 22, 2010Results posted

Local Phase 4 Pan-European SMART Study

A Phase 4 interventional study of Budesonide/formoterol in Asthma, sponsored by AstraZeneca. Completed at 819 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-03-22.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
8,424
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
Largest of 108
8,424 · median 124
Started
2007
with 11 others
Phase 4
33 of 110
3 open now
Registered
25th of 110
by date
Lead sponsor
41 of 110
AstraZeneca

Among the 110 studies testing budesonide in Asthma, this one has the largest enrollment of the 108 interventional ones that give a count, is one of 12 that started in 2007, is one of 33 in phase 4, and was the 25th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of two different maintenance doses of Symbicort Maintenance And Reliever Therapy (SMART) in adult asthmatic patients. A 6 month treatment period

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients at out-patient clinics
  • >18 years with a minimum of 6 months documented history of persistent asthma who have used inhaled glucocorticosteroids for at least one month and have a history of use in rapid-acting B2 agonists for symptom relief

Exclusion criteria

Exclusion Criteria:

  • Asthma exacerbation within the last 14 days prior to study start
  • subject aged >40 years with a smoking history of >10pack-years
  • subjects with chronic obstructive lung disease or other significant respiratory disease
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8,424 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Severe Asthma Exacerbations Per Participant.

    Time to first severe asthma exacerbation, translated to mean number of severe asthma exacerbations per participant. A severe asthma exacerbation is defined as deterioration in asthma requiring oral/systemic glucocorticosteroids for at least 3 days and/or hospitalisation/emergency room visit with oral/systemic glucocorticosteroid treatment.

    Time frame: 6 months

Secondary outcomes

  1. Fraction of Participants With Severe Asthma Exacerbation

    The total number of severe asthma exacerbations was calculated for each participant. A severe asthma exacerbation is defined as deterioration in asthma requiring oral/systemic glucocorticosteroids for at least 3 days and/or hospitalisation/emergency room visit with oral/systemic glucocorticosteroid treatment.

    Time frame: 6 months.

  2. Total Number of Severe Asthma Exacerbations That Led to Hospitalisation and/or Emergency Room Treatment.

    A severe asthma exacerbation is defined as deterioration in asthma requiring oral/systemic glucocorticosteroids for at least 3 days and/or hospitalisation/emergency room visit with oral/systemic glucocorticosteroid treatment. Number of events per participant

    Time frame: 6 months.

  3. Total Number of Days Per Participant With Oral/Systemic Glucocorticosteroids During Severe Asthma Exacerbation

    Total number of days with oral/systemic glucocorticosteroids during severe exacerbation calculated for each participant. A severe asthma exacerbation is defined as deterioration in asthma requiring oral/systemic glucocorticosteroids for at least 3 days and/or hospitalisation/emergency room visit with oral/systemic glucocorticosteroid treatment.

    Time frame: 6 months.

  4. Mean Daily Number of Inhalations of As-needed Medication.

    The number of as-needed inhalations was measured 2 times during 2 weeks before 13 weeks and 26 weeks of treatment.

    Time frame: 4 weeks

  5. Percent of Participants With a Well Controlled Asthma Week.

    The mean percent of participants fulfilling the criteria for a well controlled asthma week in each treatment. A well controlled asthma week is defined as a week with no exacerbations and no night-time awakenings due to asthma and a maximum of 2 days with symptoms and as-needed inhalation use.

    Time frame: 6 months.

  6. Mean Overall Asthma Control Questionnaire (ACQ) Score

    The ACQ5 was used. The lower value the better with a full range from 0=no impairment, 6= maximum impairment. Awakenings, morning symptoms, limitations, shortness of breath and wheeze.

    Time frame: 6 months.

  7. The Mean Total Daily Dose of Steroids From Symbicort.

    The mean total daily dose of steroids from Symbicort was calculated as the sum of the maintenance dose and the as-needed dose.

    Time frame: 4 weeks

  8. Mean Cost Per Participant Per Country

    Mean cost is calculated for each country using participants from the whole study and country specific costs. Mean value for the whole study can not be calculated.

    Time frame: 6 months

07

Results

Posted Mar 22, 2010

Participant flow

This was a 6-month, randomised, open label, parallel-group, active controlled, multinational study, in participants with uncontrolled/partly controlled asthma, who were symptomatic despite daily use of inhaled glucocorticosteroid (IGCS) with or without Long-Acting β2 agonist (LABA).

Participant flow — Overall Study
MilestoneSymbicort® SMART®) 1*2Symbicort® SMART®) 2*2
Started40084045
Completed36993705
Not completed309340
Withdrew: Adverse event7093
Withdrew: Withdrawal by subject8179
Withdrew: Lost to follow-up4655
Withdrew: Incorrect enrolment6466
Withdrew: Severe non-compliance to protocol2521
Withdrew: Safety reason13
Withdrew: Mis-randomization of subject01
Withdrew: Other2222

Outcome measures

PrimaryNumber of Severe Asthma Exacerbations Per Participant.

Time to first severe asthma exacerbation, translated to mean number of severe asthma exacerbations per participant. A severe asthma exacerbation is defined as deterioration in asthma requiring oral/systemic glucocorticosteroids for at least 3 days and/or hospitalisation/emergency room visit with oral/systemic glucocorticosteroid treatment.

Time frame:
6 months
Reported as:
Mean · Severe exacerbations per participant
Number of Severe Asthma Exacerbations Per Participant.
Severe exacerbations per participantSymbicort® SMART®) 1*2Symbicort® SMART®) 2*2
Number of Severe Asthma Exacerbations Per Participant.0.097 ± 00.080 ± 0
SecondaryFraction of Participants With Severe Asthma Exacerbation

The total number of severe asthma exacerbations was calculated for each participant. A severe asthma exacerbation is defined as deterioration in asthma requiring oral/systemic glucocorticosteroids for at least 3 days and/or hospitalisation/emergency room visit with oral/systemic glucocorticosteroid treatment.

Time frame:
6 months.
Reported as:
Mean · Fraction of participants with event
Fraction of Participants With Severe Asthma Exacerbation
Fraction of participants with eventSymbicort® SMART®) 1*2Symbicort® SMART®) 2*2
Fraction of Participants With Severe Asthma Exacerbation0.09686 ± 0.085280.07955 ± 0.06927
SecondaryTotal Number of Severe Asthma Exacerbations That Led to Hospitalisation and/or Emergency Room Treatment.

A severe asthma exacerbation is defined as deterioration in asthma requiring oral/systemic glucocorticosteroids for at least 3 days and/or hospitalisation/emergency room visit with oral/systemic glucocorticosteroid treatment. Number of events per participant

Time frame:
6 months.
Reported as:
Mean · Number of events per participant
Total Number of Severe Asthma Exacerbations That Led to Hospitalisation and/or Emergency Room Treatment.
Number of events per participantSymbicort® SMART®) 1*2Symbicort® SMART®) 2*2
Total Number of Severe Asthma Exacerbations That Led to Hospitalisation and/or Emergency Room Treatment.0.0120 ± 00.0091 ± 0
SecondaryTotal Number of Days Per Participant With Oral/Systemic Glucocorticosteroids During Severe Asthma Exacerbation

Total number of days with oral/systemic glucocorticosteroids during severe exacerbation calculated for each participant. A severe asthma exacerbation is defined as deterioration in asthma requiring oral/systemic glucocorticosteroids for at least 3 days and/or hospitalisation/emergency room visit with oral/systemic glucocorticosteroid treatment.

Time frame:
6 months.
Reported as:
Mean · Days per participant
Total Number of Days Per Participant With Oral/Systemic Glucocorticosteroids During Severe Asthma Exacerbation
Days per participantSymbicort® SMART®) 1*2Symbicort® SMART®) 2*2
Total Number of Days Per Participant With Oral/Systemic Glucocorticosteroids During Severe Asthma Exacerbation9.6 ± 8.19.1 ± 5.5
SecondaryMean Daily Number of Inhalations of As-needed Medication.

The number of as-needed inhalations was measured 2 times during 2 weeks before 13 weeks and 26 weeks of treatment.

Time frame:
4 weeks
Reported as:
Mean · Inhalations per day per participant
Mean Daily Number of Inhalations of As-needed Medication.
Inhalations per day per participantSymbicort® SMART®) 1*2Symbicort® SMART®) 2*2
Mean Daily Number of Inhalations of As-needed Medication.0.897 ± 00.625 ± 0
SecondaryPercent of Participants With a Well Controlled Asthma Week.

The mean percent of participants fulfilling the criteria for a well controlled asthma week in each treatment. A well controlled asthma week is defined as a week with no exacerbations and no night-time awakenings due to asthma and a maximum of 2 days with symptoms and as-needed inhalation use.

Time frame:
6 months.
Reported as:
Mean · Percentage of participants
Percent of Participants With a Well Controlled Asthma Week.
Percentage of participantsSymbicort® SMART®) 1*2Symbicort® SMART®) 2*2
Percent of Participants With a Well Controlled Asthma Week.43.69 ± 054.26 ± 0
SecondaryMean Overall Asthma Control Questionnaire (ACQ) Score

The ACQ5 was used. The lower value the better with a full range from 0=no impairment, 6= maximum impairment. Awakenings, morning symptoms, limitations, shortness of breath and wheeze.

Time frame:
6 months.
Reported as:
Mean · Scores in a scale
Mean Overall Asthma Control Questionnaire (ACQ) Score
Scores in a scaleSymbicort® SMART®) 1*2Symbicort® SMART®) 2*2
Mean Overall Asthma Control Questionnaire (ACQ) Score1.18 ± 01.089 ± 0
SecondaryThe Mean Total Daily Dose of Steroids From Symbicort.

The mean total daily dose of steroids from Symbicort was calculated as the sum of the maintenance dose and the as-needed dose.

Time frame:
4 weeks
Reported as:
Mean · μg budesonide per day
The Mean Total Daily Dose of Steroids From Symbicort.
μg budesonide per daySymbicort® SMART®) 1*2Symbicort® SMART®) 2*2
The Mean Total Daily Dose of Steroids From Symbicort.462.96 ± 179.10736.58 ± 152.70
SecondaryMean Cost Per Participant Per Country

Mean cost is calculated for each country using participants from the whole study and country specific costs. Mean value for the whole study can not be calculated.

Time frame:
6 months
Reported as:
Mean · Euro

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Symbicort® SMART®) 1*2—77/4,008 (1.9%)0/4,008 (0%)
Symbicort® SMART®) 2*2—88/4,045 (2.2%)0/4,045 (0%)
Most frequent serious events
Showing 10 of 115
Most frequent serious events
EventSymbicort® SMART®) 1*2Symbicort® SMART®) 2*2
AsthmaRespiratory, thoracic and mediastinal disorders13/40089/4045
CholelithiasisHepatobiliary disorders0/40084/4045
Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/40084/4045
PneumoniaInfections and infestations3/40083/4045
OsteoarthritisMusculoskeletal and connective tissue disorders3/40083/4045
Atrial FibrillationCardiac disorders2/40081/4045
ColitisGastrointestinal disorders2/40080/4045
DiarrhoeaGastrointestinal disorders2/40080/4045
Chest PainGeneral disorders2/40081/4045
CataractEye disorders0/40082/4045

Baseline characteristics

Age Continuous
Age Continuous(Years)Symbicort® SMART®) 1*2Symbicort® SMART®) 2*2Total
Mean47.8 (18 to 96)47.9 (18 to 90)47.8 (18 to 96)
Sex: Female, Male
Sex: Female, Male(Participants)Symbicort® SMART®) 1*2Symbicort® SMART®) 2*2Total
Female248325124995
Male152515333058
Treatment with Long-Acting β2 agonist (LABA) at baseline.
Treatment with Long-Acting β2 agonist (LABA) at baseline.(Participants)Symbicort® SMART®) 1*2Symbicort® SMART®) 2*2Total
Number of participants using LABA at baseline.310831186226
Number of participants without LABA at baseline.9009271827
Asthma control questionnaire (ACQ5) score at study entry
Asthma control questionnaire (ACQ5) score at study entry(Units on a scale)Symbicort® SMART®) 1*2Symbicort® SMART®) 2*2Total
ACQ5 score at study entry1.85 ± 0.981.86 ± 1.011.85 ± 0.99
Exacerbations past 12 months before study start.
Exacerbations past 12 months before study start.(Number of exacerbations per participant)Symbicort® SMART®) 1*2Symbicort® SMART®) 2*2Total
Mean1.47 ± 2.421.42 ± 2.421.45 ± 2.42
Inhaled glucocorticosteroids (IGCS) dose at study entry.
Inhaled glucocorticosteroids (IGCS) dose at study entry.(μg/day)Symbicort® SMART®) 1*2Symbicort® SMART®) 2*2Total
IGCS dose at study entry1046 ± 5951037 ± 5751042 ± 585
Participants with a well controlled asthma week at study entry.
Participants with a well controlled asthma week at study entry.(Percentage of participants)Symbicort® SMART®) 1*2Symbicort® SMART®) 2*2Total
Mean11.97 (0 to 100)11.77 (0 to 100)11.87 (0 to 100)
Pulmonary function test at baseline.
Pulmonary function test at baseline.(Percent of predicted normal value of PEF)Symbicort® SMART®) 1*2Symbicort® SMART®) 2*2Total
Percent Included90.8 (0 to 100)90.1 (0 to 100)90.4 (0 to 100)
08

Study locations

819 sites
  • Research Site
    Aalst, Belgium
  • Research Site
    Aarschot, Belgium
  • Research Site
    Aatrijken, Belgium
  • Research Site
    Asse, Belgium
  • Research Site
    Balen, Belgium
  • Research Site
    Bastogne, Belgium
  • Research Site
    Bellaire, Belgium
  • Research Site
    Betrix, Belgium
  • Research Site
    Binche, Belgium
  • Research Site
    Blankenberge, Belgium
  • Research Site
    Boortmeerbeek, Belgium
  • Research Site
    Bornem, Belgium
  • Research Site
    Boussu, Belgium
  • Research Site
    Brugge, Belgium
  • Research Site
    Bruxelles, Belgium
  • Research Site
    Buizingen, Belgium
  • Research Site
    Burdinne, Belgium
  • Research Site
    Champion, Belgium
  • Research Site
    Charleroi, Belgium
  • Research Site
    Chatelet, Belgium
  • Research Site
    Chenee, Belgium
  • Research Site
    Dendermonde, Belgium
  • Research Site
    Diksmuide, Belgium
  • Research Site
    Drongen, Belgium
  • Research Site
    Duffel, Belgium
  • Research Site
    Edegem, Belgium
  • Research Site
    Eeklo, Belgium
  • Research Site
    Ekeren, Belgium
  • Research Site
    Erembodegem, Belgium
  • Research Site
    Evergem, Belgium
  • Research Site
    Fleurus, Belgium
  • Research Site
    Gembloux, Belgium
  • Research Site
    Genk, Belgium
  • Research Site
    Gent, Belgium
  • Research Site
    Gilly, Belgium
  • Research Site
    Graty, Belgium
  • Research Site
    Grivegnee, Belgium
  • Research Site
    Halle, Belgium
  • Research Site
    Ham-sur-Heure, Belgium
  • Research Site
    Ham, Belgium
  • Research Site
    Hasselt, Belgium
  • Research Site
    Havinnes, Belgium
  • Research Site
    Heist-op-Den-Berg, Belgium
  • Research Site
    Herentals, Belgium
  • Research Site
    Herstal, Belgium
  • Research Site
    Hoboken, Belgium
  • Research Site
    Hoeselt, Belgium
  • Research Site
    Hooglede, Belgium
  • Research Site
    Hornu, Belgium
  • Research Site
    Houthalen-Helchteren, Belgium
  • Research Site
    Huldenberg, Belgium
  • Research Site
    Izegem, Belgium
  • Research Site
    Jambes, Belgium
  • Research Site
    Jodoigne, Belgium
  • Research Site
    Kinrooi, Belgium
  • Research Site
    Kontich, Belgium
  • Research Site
    Kraainem, Belgium
  • Research Site
    La Louviere, Belgium
  • Research Site
    Langdorp, Belgium
  • Research Site
    Lauwe, Belgium
  • Research Site
    Leopoldsburg, Belgium
  • Research Site
    Leuven, Belgium
  • Research Site
    Liege, Belgium
  • Research Site
    Lier, Belgium
  • Research Site
    Lommel, Belgium
  • Research Site
    Lovendegem, Belgium
  • Research Site
    Malmedy, Belgium
  • Research Site
    Marchovelette, Belgium
  • Research Site
    Meelbeke, Belgium
  • Research Site
    Moerkerke, Belgium
  • Research Site
    Mol, Belgium
  • Research Site
    Monceau-sur-Sambre, Belgium
  • Research Site
    Mons, Belgium
  • Research Site
    Montegnee, Belgium
  • Research Site
    Moorsel, Belgium
  • Research Site
    Mouscron, Belgium
  • Research Site
    Namur, Belgium
  • Research Site
    Natoye, Belgium
  • Research Site
    Nijlen, Belgium
  • Research Site
    Nivelles, Belgium
  • Research Site
    Oedelem, Belgium
  • Research Site
    Oostende, Belgium
  • Research Site
    Oostkamp, Belgium
  • Research Site
    Oppuurs, Belgium
  • Research Site
    Oudenaarde, Belgium
  • Research Site
    Paal, Belgium
  • Research Site
    Peutie, Belgium
  • Research Site
    Poederlee, Belgium
  • Research Site
    Pulle, Belgium
  • Research Site
    Rijkevorsel, Belgium
  • Research Site
    Rixensart, Belgium
  • Research Site
    Rotselaar, Belgium
  • Research Site
    Roux, Belgium
  • Research Site
    Sijsele, Belgium
  • Research Site
    Sint-Genesius-Rode, Belgium
  • Research Site
    Sint-Niklaas, Belgium
  • Research Site
    St Katharina Lombeek, Belgium
  • Research Site
    St-Vith, Belgium
  • Research Site
    Steenokkerzeel, Belgium
  • Research Site
    Stekene, Belgium

Showing the first 100 of 819 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Aubier M, Haughney J, Selroos O, van Schayck OC, Ekstrom T, Ostinelli J, Buhl R. Is the patient's baseline inhaled steroid dose a factor for choosing the budesonide/formoterol maintenance and reliever therapy regimen? Ther Adv Respir Dis. 2011 Oct;5(5):289-98. doi: 10.1177/1753465811407236. Epub 2011 May 17. Erratum In: Ther Adv Respir Dis. 2012 Aug;6(4):247. PubMed 21586508 ↗
  • Haughney J, Aubier M, Jorgensen L, Ostinelli J, Selroos O, van Schayck CP, Buhl R. Comparing asthma treatment in elderly versus younger patients. Respir Med. 2011 Jun;105(6):838-45. doi: 10.1016/j.rmed.2011.02.011. Epub 2011 Mar 23. PubMed 21435854 ↗
  • Aubier M, Buhl R, Ekstrom T, Ostinelli J, van Schayck CP, Selroos O, Haughney J. Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy. Eur Respir J. 2010 Sep;36(3):524-30. doi: 10.1183/09031936.00022010. Epub 2010 Jul 1. PubMed 20595145 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2007
First posted
Apr 20, 2007
Start
Mar 2007
CompletionActual
Dec 2008
Results first posted
Mar 22, 2010
Last update
Mar 22, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00463866
Lead sponsor
AstraZeneca
First posted
Apr 20, 2007
Start date
Mar 2007
Completion
Dec 2008
Results posted
Mar 22, 2010
Last update
Mar 22, 2010

Study contacts

Michel Aubier, Prof
principal investigator · FRANCE
Juliette Ostinelli, MD
study chair · AstraZeneca, MC France
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Formoterol

Start the discussion